Sigilon Therapeutics, Inc., a biopharmaceutical company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate-severe to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neurological manifestations of the disease in patients with mucopolysaccharidosis type 1; SIG-007 to provide continuous and prolonged release of functional enzyme at levels sufficient to produce clinical benefits and alleviate progression of the downstream aspects of Fabry disease; and SIG-002 designed to replace islet cells for the treatment of type 1 diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017. Sigilon Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.
IPO Year: 2020
Exchange: NASDAQ
Website: sigilon.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/23/2021 | $12.00 → $7.00 | Buy | Canaccord Genuity |
| 12/1/2021 | $16.00 → $7.00 | Overweight | Barclays |
| 11/30/2021 | $9.00 → $4.50 | Equal-Weight | Morgan Stanley |
| 11/30/2021 | $15.00 → $4.00 | Buy → Hold | Jefferies |
| 10/29/2021 | $14.00 | Buy | BTIG |
| 8/2/2021 | $15.00 | Buy | Jefferies |
| 7/19/2021 | $62.00 → $43.00 | Buy | Canaccord Genuity |
| 7/16/2021 | $45.00 → $9.00 | Equal-Weight | Morgan Stanley |
SC 13G/A - Sigilon Therapeutics, Inc. (0001821323) (Subject)
SC 13D/A - Sigilon Therapeutics, Inc. (0001821323) (Subject)
SC 13D - Sigilon Therapeutics, Inc. (0001821323) (Subject)
SC 13G - Sigilon Therapeutics, Inc. (0001821323) (Subject)
SC 13G - Sigilon Therapeutics, Inc. (0001821323) (Subject)
Canaccord Genuity reiterated coverage of Sigilon Therapeutics with a rating of Buy and set a new price target of $7.00 from $12.00 previously
Barclays reiterated coverage of Sigilon Therapeutics with a rating of Overweight and set a new price target of $7.00 from $16.00 previously
Morgan Stanley reiterated coverage of Sigilon Therapeutics with a rating of Equal-Weight and set a new price target of $4.50 from $9.00 previously
Jefferies downgraded Sigilon Therapeutics from Buy to Hold and set a new price target of $4.00 from $15.00 previously
BTIG initiated coverage of Sigilon Therapeutics with a rating of Buy and set a new price target of $14.00
Jefferies resumed coverage of Sigilon Therapeutics with a rating of Buy and set a new price target of $15.00
Canaccord Genuity reiterated coverage of Sigilon Therapeutics with a rating of Buy and set a new price target of $43.00 from $62.00 previously
Morgan Stanley reiterated coverage of Sigilon Therapeutics with a rating of Equal-Weight and set a new price target of $9.00 from $45.00 previously
CAMBRIDGE, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today reported financial results for the first quarter ended March 31, 2021 as well as certain other business highlights. "We are continuing to execute on our business plan in 2021, as we advance the clinical development of our lead product candidate for hemophilia A, while at the same time working to strengthen our team, expanding our pipeline and further validating the potential of our Shielded Living Therapeutics™, or SLTx, platform," commented Rogerio Vivald
4 - Sigilon Therapeutics, Inc. (0001821323) (Issuer)
4 - Sigilon Therapeutics, Inc. (0001821323) (Issuer)
4 - Sigilon Therapeutics, Inc. (0001821323) (Issuer)
4 - Sigilon Therapeutics, Inc. (0001821323) (Issuer)
4 - Sigilon Therapeutics, Inc. (0001821323) (Issuer)
4 - Sigilon Therapeutics, Inc. (0001821323) (Issuer)
4 - Sigilon Therapeutics, Inc. (0001821323) (Issuer)
4 - Sigilon Therapeutics, Inc. (0001821323) (Issuer)
4 - Sigilon Therapeutics, Inc. (0001821323) (Issuer)
4 - Sigilon Therapeutics, Inc. (0001821323) (Issuer)
15-12G - Sigilon Therapeutics, Inc. (0001821323) (Filer)
EFFECT - Sigilon Therapeutics, Inc. (0001821323) (Filer)
S-8 POS - Sigilon Therapeutics, Inc. (0001821323) (Filer)
S-8 POS - Sigilon Therapeutics, Inc. (0001821323) (Filer)
S-8 POS - Sigilon Therapeutics, Inc. (0001821323) (Filer)
S-8 POS - Sigilon Therapeutics, Inc. (0001821323) (Filer)
POS AM - Sigilon Therapeutics, Inc. (0001821323) (Filer)
8-K - Sigilon Therapeutics, Inc. (0001821323) (Filer)
25-NSE - Sigilon Therapeutics, Inc. (0001821323) (Subject)
SC TO-T/A - Sigilon Therapeutics, Inc. (0001821323) (Subject)
Werner Brings More Than Two Decades of Pharmaceutical Leadership to the Role CAMBRIDGE, Mass., April 11, 2022 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today announced it has strengthened its executive leadership team with the appointment of Michelle C. Werner to the dual role of CEO-Partner of Flagship Pioneering and Chief Executive Officer of Alltrna. Werner brings to Flagship significant experience as a global pharmaceutical leader spanning both Commercial and Research and Development (R&D) responsibilities. Werner most recently served as Wo
Announced strategic reprioritization, with plans to advance mucopolysaccharidosis type I (MPS-1) and diabetes as lead indications as well as continued platform optimization Strengthened leadership team with appointment of new Chief Technical Operations Officer and other key leadership changes Current cash position expected to fund operating plans into 2024 CAMBRIDGE, Mass., March 14, 2022 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today reported financial results for the fourth quarter and full year ended December 31, 2021 as well as
CAMBRIDGE, Mass., Feb. 28, 2022 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of Anne Pariser, M.D., as Vice President, Medical and Regulatory Affairs. Prior to joining Alltrna, Dr. Pariser was the Director of the Office of Rare Diseases Research (ORDR) at the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH), whose mission is to advance rare diseases research through a variety of research programs. Prior to ORDR, she worked at the U.S. Food and Drug Administration (FDA) Center for
CAMBRIDGE, Mass., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced the appointment of Sarah Yuan, Ph.D., as Chief Technical Operations Officer, effective March 7th, 2022. Dr. Yuan brings more than 20 years of experience in process development, manufacturing sciences and CMC strategies from a broad range of leading biopharmaceutical companies. "We are delighted to welcome Sarah, a biopharma veteran, to the Sigilon team," said Rogerio Vivaldi, M.D., President and CEO of Sigilon. "Sarah has an impressive track recor
CAMBRIDGE, Mass., Feb. 15, 2022 /PRNewswire/ -- Invaio Sciences, Inc., a Flagship Pioneering company focused on unlocking the potential of the planet's interdependent natural systems to solve pressing agricultural, sustainability, and environmental challenges, today announced the appointment of Hugh Grant to its Board of Directors. Grant brings nearly 40 years of agricultural and corporate leadership, including as Chairman, President, and Chief Executive Officer of the former Monsanto Company, a global provider of technology-based solutions and agricultural products. During h
CAMBRIDGE, Mass., Jan. 26, 2022 /PRNewswire/ -- Senda Biosciences, Inc., a company that is harnessing nature to program targeted, potent and tunable medicines, has appointed Stuart Milstein, Ph.D., to the newly created position of Senior Vice President and Head of Platform Biology. Dr. Milstein most recently served as the Vice President of platform biology at Korro Bio, Inc., and previously led the RNAi Lead Development group at Alnylam Pharmaceuticals, Inc. Dr. Milstein will be responsible for advancing Senda's platform and scaling the Company's efforts to unlock a new class of fully programmable medicines.
CAMBRIDGE, Mass., Jan. 25, 2022 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, announced today that Tom DiLenge has joined the company in a newly created role as Senior Partner, Global Public Policy, Regulatory & Governmental Strategy. In this role, DiLenge will lead and develop Flagship's public policy, regulatory, and government affairs functions to advance Flagship's priorities at the federal, state, and global levels. In addition, he will serve as an in-house advisor and expert resource to Flagship's ecosystem companies. Tom brings to Flagship Pi
Estepan brings to Cellarity's BOD deep experience and expertise in all aspects of finance, corporate strategy, investor relations, and business development, and a dedication to directly improving patient lives through innovation in medicine Cellarity, a life sciences company founded by Flagship Pioneering to transform the way medicines are discovered, announced today the appointment of Ian M. Estepan to its Board of Directors. Mr. Estepan currently serves as Executive Vice President and Chief Financial Officer (CFO) of Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases. At Sarepta and as a member of Sarepta's Executive Committee, he leads f
CAMBRIDGE, Mass., Nov. 15, 2021 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, announced today that Justine Levin-Allerhand, Ph.D., has joined the company in a newly created role as Senior Partner, Corporate Development. In this role, Levin-Allerhand will develop, lead, and implement best practices in Board governance, Board development, and Board member selection and recruitment across Flagship's enterprise of companies. In addition, she will advance corporate development broadly, including building new relationships with limited partners and building partnerships with aligned research and academic institutions.
Company expects to complete its investigation of the clinical hold on its Phase 1/2 trial of SIG-001 in hemophilia A by year-end On track to initiate a Phase 1/2 trial of SIG-005 for MPS-1 in the fourth quarter of 2021 Company appoints May Orfali, M.D., M.B.A, as Chief Medical Officer CAMBRIDGE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today reported financial results for the third quarter ended September 30, 2021 as well as certain other business highlights. "In the third quarter, we made
INDIANAPOLIS, Aug. 14, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Sigilon Therapeutics, Inc. (NASDAQ:SGTX). The acquisition allows Lilly to continue researching and developing encapsulated cell therapies, including SIG-002, for the treatment of type 1 diabetes. "Make life better – that's the phrase that guides everything we do at Lilly," said Ruth Gimeno, Ph.D., group vice president, diabetes, obesity and cardiometabolic research at Lilly. "We are excited to welcome our new colleagues from Sigilon to Lilly; together, we will strive to provide solutions for people living with type 1 diabetes that absolves them of cons
NEW YORK, July 15, 2023 (GLOBE NEWSWIRE) -- Kaleyra, Inc. (NYSE:KLR) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of KLR to Tata Communications Limited for $7.25 per share in cash. If you are a KLR investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected]. Conformis Inc. (NASDAQ:CFMS) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of CFMS to Restor3d, Inc. for $2.27 per share in cash.
INDIANAPOLIS and CAMBRIDGE, Mass., June 29, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) and Sigilon Therapeutics, Inc. (NASDAQ:SGTX) today announced a definitive agreement for Lilly to acquire Sigilon, a biopharmaceutical company that seeks to develop functional cures for patients with a broad range of acute and chronic diseases. Since 2018, Lilly and Sigilon have worked together to develop encapsulated cell therapies, including SIG-002, for the treatment of type 1 diabetes. The goal of these therapies is to free patients from constant disease management by sensing blood glucose levels, restoring insulin production and releasing it over the long term. "Despite significant advanceme
CAMBRIDGE, Mass., May 22, 2023 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX) today announced it will effect a one-for-13 reverse stock split of its issued and outstanding common stock. Sigilon stockholders approved an amendment to Sigilon's Fifth Amended and Restated Certificate of Incorporation to effect the reverse stock split at Sigilon's Annual Meeting of Stockholders held on May 19, 2023. The reverse stock split is intended to increase the per share trading price of Sigilon's common stock to enable Sigilon to satisfy the minimum price requirement for continued listing on the Nasdaq Global Select Market. Sigilon expects that upon the opening of trading on May 23, 2023, i
SIG-002, Sigilon's lead program for the treatment of diabetes, transitioning to IND-enabling and NHP studies in the second half of 2023 Pipeline prioritization extends anticipated cash runway into 2025 CAMBRIDGE, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today reported financial results for the first quarter ended March 31, 2023 as well as certain other business highlights. "In the first quarter, we prioritized our diabetes program, SIG-002, which we are advancing with Eli Lilly and Company. With Lilly reimbursing
CHICAGO, May 2, 2023 /PRNewswire/ -- Dimension Inx, a biomaterials platform company developing therapeutics that restore tissue and organ function, announced today the appointments of Paul K. Wotton, Ph.D., to the board of directors and Chris Ehrlich as Senior Advisor. Dr. Wotton fills the role of Independent Director of the Board, created following Dimension's Series A raise of $15M completed in February 2023. He brings an expert perspective on platform growth opportunities as a leader of multiple global biotechnology and pharmaceutical companies. Dr. Wotton is a serial entrepreneur and inventor with experience spanning scientific research, product development, and transformational busines
CAMBRIDGE, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for acute and chronic diseases through its Shielded Living Therapeutics™ platform, today announced that its President and Chief Executive Officer, Rogerio Vivaldi, M.D., will present a corporate overview during the Needham Virtual Healthcare Conference. The presentation will take place on Thursday, April 20, 2023 at 10:15 a.m. EDT. A webcast of the presentation will be accessible through the investor section of the company's website at www.sigilon.com, with a replay available for 90 days following the event. About Sigilon Therapeuti
Advancing IND-enabling activities for lead program in diabetes, SIG-002, with plans to conduct non-human primate studies in second half of 2023 SIG-002 demonstrated efficacy and durability in in vivo mouse models for up to 17 weeks Extended anticipated cash runway into 2025 CAMBRIDGE, Mass., March 14, 2023 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today reported financial results for the fourth quarter and year ended December 31, 2022 as well as certain other business highlights. "Reflecting on 2022, we made many important strategic
Identified important optimization features for its platform to mitigate PFO risks in current and future programs Advanced iPS cell differentiation protocol for the diabetes program in preparation for anticipated IND-enabling studies in 2023 Continued optimization of the MPS-1 program, with plans to initiate IND-enabling studies in the second half of 2023 CAMBRIDGE, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today reported financial results for the third quarter ended September 30, 2022 as well as certain ot
CAMBRIDGE, Mass., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today reported financial results for the second quarter ended June 30, 2022 as well as certain other business highlights. "During the second quarter, we remained focused on completing the preclinical work that will help shape our clinical strategy moving forward. We are presently conducting numerous preclinical studies designed to further evaluate the pericapsular fibrotic overgrowth observed in our hemophilia program. Based on the results of these novel experi